Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Marcus Yountz, MD
Alexion Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
60 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Buenos Aires, Argentina
- Facility name not stated
Edegem, Belgium
- Facility name not stated
Ghent, Belgium
- Facility name not stated
Leuven, Belgium
- Facility name not stated
São Paulo, Brazil
- Facility name not stated
Edmonton, Canada
- Facility name not stated
Ostrava - Poruba, Czechia
- Facility name not stated
Prague, Czechia
- Facility name not stated
Arhus C, Denmark
- Facility name not stated
Copenhagen, Denmark
- Facility name not stated
Turku, Finland
- Facility name not stated
Szeged, Hungary
- Facility name not stated
Milan, Italy
- Facility name not stated
Naples, Italy
- Facility name not stated
Roma, Italy
- Facility name not stated
Chiba, Japan
- Facility name not stated
Fukuoka, Japan
- Facility name not stated
Hanamaki, Japan
- Facility name not stated
Hokkaido, Japan
- Facility name not stated
Miyagi, Japan
- Facility name not stated
Nagasaki, Japan
- Facility name not stated
Osaka, Japan
- Facility name not stated
Osaka-Fu, Japan
- Facility name not stated
Amsterdam, Netherlands
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Barcelona, Spain
- Facility name not stated
Madrid, Spain
- Facility name not stated
Stockholm, Sweden
- Facility name not stated
Ankara, Turkey (Türkiye)
- Facility name not stated
Izmir, Turkey (Türkiye)
- Facility name not stated
Kocaeli, Turkey (Türkiye)
- Facility name not stated
Birmingham, United Kingdom
- Facility name not stated
Liverpool, United Kingdom
- Facility name not stated
London, United Kingdom
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Orange, California, United States
- Facility name not stated
Palo Alto, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
New Haven, Connecticut, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Nov 2014
- Primary completion
- 15 Jan 2019
- Completion
- 15 Jan 2019
- Last update posted
- 5 Feb 2020
- Registered enrollment
- 117
- Registry id
- NCT02301624
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.